Bydureon Warning for MTC and Acute Pancreatitis

Print Friendly, PDF & Email
The FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary to ensure that the benefits of Bydureon (exenatide extended-release for injectable suspension; Amylin) outweigh the potential risks including  medullary thyroid carcinoma (MTC) and acute pancreatitis.

Read Full Article from Source →

© Copyright 2013 Endoscopy Center. All Rights Reserved Privacy Policy | Site Map

Back to the Top